Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

CORTIMENT PROLONGED RELEASE TABLETS 9 MG [SIN15311P]

Active ingredients: (TABLET CORE) BUDESONIDE MICRONIZED

View product's general information
Last updated on 9 October 2026

Product Info

CORTIMENT PROLONGED RELEASE TABLETS 9 MG

[SIN15311P]

Product information

Active Ingredient and Strength

(TABLET CORE) BUDESONIDE MICRONIZED - 9 MG

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Manufacturer and Country

COSMO SPA - ITALY

Registration Number

SIN15311P

Licence Holder

FERRING PHARMACEUTICALS PRIVATE LIMITED

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

A07EA06

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

THERAPEUTIC INDICATIONS
Budesonide (CORTIMENT) is indicated in adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient.

Dosing

POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Adults
The recommended daily dose for induction of remission is one 9 mg tablet in the morning, for up to 8 weeks.

When treatment is discontinued, it may be useful to gradually reduce the dose (for more details on treatment discontinuation, see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Paediatric population
The safety and efficacy of Budesonide (CORTIMENT) tablets in children aged 0–18 years have not yet been established. No data are available, therefore the use in paediatric population is not recommended until further data become available.

Elderly
No special dose adjustment is recommended. However, experience of the use of Budesonide (CORTIMENT) in the elderly is limited.

Hepatic and renal impairment population
Budesonide (CORTIMENT) 9 mg was not studied in patients with hepatic and renal impairment, therefore caution should be exercised in the administration and monitoring of the product in these patients (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Method of administration
One tablet of Budesonide (CORTIMENT) 9 mg is taken orally in the morning, with or without food. The tablet should be swallowed with a glass of water and must not be broken, crushed or chewed as the film coating is intended to ensure a prolonged release.

Contraindications

CONTRAINDICATIONS
Hypersensitivity to the active substance, lecithin (derived from soya oil, peanut oil) or any of the excipients listed in section LIST OF EXCIPIENTS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.